PT-141 peptide side effects: what the trials actually found

Last updated 2026-07-24

What are the most common PT-141 peptide side effects?

Nausea is the big one. Across the two phase 3 trials that got bremelanotide approved as Vyleesi, nausea was reported by roughly 40% of women in the treatment group, compared to under 3% on placebo ^[1]. Flushing came in second at about 20%, and injection site reactions plus headache showed up at meaningfully lower rates ^[1][2]. The safety pooling across bremelanotide's full clinical development program (more than the two main trials, and the earlier dose-finding work too) confirms the same pattern: nausea and flushing dominate the side effect list, and both tend to be dose-related ^[2]. In the phase 2b dose-ranging study, higher doses produced more nausea, and a meaningful share of women who got nausea at the top dose tested actually stopped the drug over it ^[3]. Here's the honest part: nausea isn't a rare footnote you'll skim past in a package insert. It's the single most likely thing you'll notice, and for some people it's bad enough on the first dose to color their whole opinion of the drug. | Side effect | Approximate rate on bremelanotide | Approximate rate on placebo |

Why does PT-141 cause nausea and flushing? (it's not like sildenafil)

This is the part worth actually understanding, because it changes what you should expect. PT-141 doesn't work on blood vessels the way sildenafil (Viagra) does. Sildenafil is vascular: it blocks an enzyme (PDE5) so blood flow increases locally, mostly useful for erectile physiology. Bremelanotide is central. It activates melanocortin receptors, mainly MC4R, in the brain ^[4][5]. Those receptors sit in pathways that also touch appetite, energy balance, and autonomic tone, which is exactly why the drug's side effects look different from a vascular drug's side effects. Nausea and flushing are downstream of a brain receptor being activated, not a blood vessel being dilated ^[4]. The melanocortin system is the same one being explored for metabolic disease and obesity, because MC4R signaling touches appetite regulation ^[6]. That's not a coincidence. Phase 1 data in obese women actually looked at bremelanotide's effect on body weight, separate from its sexual desire indication, and found modest weight effects tied to the same receptor activity ^[7]. None of that means PT-141 is a weight loss drug (it isn't approved for that), but it explains why the side effect profile leans nausea and appetite-adjacent rather than cardiovascular. If you want the deeper mechanism explanation, we cover it in pt 141 peptide.

How common is nausea with PT-141, and does it get better?

Nausea affected close to 40% of women on bremelanotide in the RECONNECT trials, versus roughly 1-3% on placebo ^[1]. That's a big gap, and it's the number to actually plan around. The pattern reported in the safety pooling analysis is that nausea is worst with the first one or two doses and tends to fade with continued use ^[2]. That lines up with what's seen in the phase 2b dose-ranging data, where nausea was clearly dose-dependent, meaning lower doses produced less of it ^[3]. It's also the leading reason people stop the drug voluntarily. A few practical points that show up across the trial data: Taking the dose on an empty stomach doesn't reliably reduce nausea; the mechanism is central, not gastric. Some women reduce nausea by never exceeding one dose in 24 hours (the labeled maximum) and spacing doses further apart than the minimum interval. Nausea severity in the trials was mostly mild to moderate, not the kind requiring medical treatment, but it was common enough that trial authors flagged it as the main tolerability issue ^[1][2]. If nausea is severe or doesn't ease after a few doses, that's worth a conversation with the prescribing clinician rather than pushing through it.

What are PT-141 nasal spray side effects specifically?

Nasal spray formulations of bremelanotide were studied in earlier development, including trials from 2006 that looked at intranasal dosing before the subcutaneous injection became the approved route ^[8]. The nasal route showed the same core side effects: nausea and flushing, plus some nasal-specific irritation. Here's the important distinction for anyone searching "PT-141 nasal spray side effects": Vyleesi, the FDA-approved version, is a subcutaneous auto-injector, not a nasal spray ^[9][10]. Nasal spray PT-141 products sold outside that approval pathway aren't FDA-approved formulations, and their dosing, purity, and absorption aren't standardized the way an approved drug's are. That matters because nausea and flushing rates from approved trial data don't necessarily transfer cleanly to a different delivery method with different absorption kinetics. Early research also looked at other delivery formats, including a 2025 study on a dissolvable buccal patch designed for peptide delivery through the cheek ^[11]. That's a research device, not an approved product, and it points to a broader pattern: how a peptide gets into the body changes its side effect timing and intensity, even if the molecule is identical.

Does PT-141 raise blood pressure? What about heart-related side effects?

Yes, transiently. Bremelanotide causes a temporary, dose-related rise in blood pressure after each dose, which is why it's not recommended for people with uncontrolled hypertension or known cardiovascular disease ^[12]. This is a labeled consideration, not a rare or occult risk. A 2022 review on managing hypertension alongside female sexual dysfunction specifically flags bremelanotide's transient blood pressure effect as something clinicians need to screen for before prescribing ^[12]. The rise is short-lived (hours, tied to the dosing window) rather than a sustained increase in baseline blood pressure, but it means the drug isn't a fit for everyone. This is also where PT-141 diverges most clearly from sildenafil-class drugs, which primarily carry vascular risks around blood pressure drops when combined with nitrates. Bremelanotide's cardiovascular signal runs the other direction: a temporary increase, tied to its central mechanism rather than direct vessel dilation ^[4][12].

Are PT-141 side effects different for men than for women?

Vyleesi is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) ^[9][10]. It is not FDA-approved for men. Any use in men is off-label, and the side effect data specific to men is much thinner than the women's trial data behind the approval. The mechanism (central melanocortin receptor activation) is the same regardless of sex, so it's reasonable to expect the same broad side effect categories: nausea, flushing, headache, and transient blood pressure increase. But the rates reported in the RECONNECT trials ^[1] and the pooled safety analysis ^[2] come entirely from a female HSDD population. Nobody has published phase 3-quality safety data in men at the scale that exists for women. That gap matters for anyone searching "PT-141 peptide for men side effects": what you'll find online is largely user-reported and anecdotal, not trial-controlled. If you're considering it off-label, that uncertainty is worth naming out loud rather than assuming the female trial rates apply one-to-one.

What side effects mean you should stop taking PT-141 and call a doctor?

Severe or worsening nausea that doesn't ease after the first few doses is the most common reason to stop and reassess with a clinician. It was also the leading cause of discontinuation in the phase 2b dose-ranging trial ^[3]. Other signals worth treating seriously: focal hyperpigmentation (darkening of skin, particularly on the face, gums, or breasts) has been reported with repeated dosing in the clinical development program, and the pooled safety data flags it as something to monitor, since it may not fully reverse after stopping ^[2]. Significant or sustained blood pressure elevation, rather than the expected transient rise, also warrants stopping and checking in ^[12]. None of the trial data suggests bremelanotide causes life-threatening reactions at labeled doses in appropriately screened patients. But "screened" is doing real work in that sentence: the trials excluded people with uncontrolled hypertension and cardiovascular disease ^[12], which is exactly why that screening step matters before starting.

How do PT-141 side effects compare to flibanserin (Addyi), the other HSDD drug?

They don't overlap much, which is part of why regulators and researchers keep comparing them. Flibanserin is a daily oral pill with sedation, dizziness, and a strict alcohol warning; bremelanotide is an as-needed injection with nausea and flushing as its signature effects ^[13][14]. A 2021 analysis in Drug and Therapeutics Bulletin pushed back on how these two drugs got compared to each other during approval, arguing that using flibanserin as a regulatory precedent for bremelanotide (or vice versa) glossed over real differences in both efficacy size and side effect character ^[13]. A separate re-analysis of the phase 3 bremelanotide trials raised similar concerns about how much the drug actually moves the needle on desire scores relative to its side effect burden ^[15]. That's a legitimate, published critique, not fringe skepticism: a 2024 paper in the Journal of Sex Research is literally titled "Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder" ^[16]. It's worth reading before deciding this is a slam-dunk treatment for everyone with low desire. For dosing specifics once you and a clinician have made that call, see our pt-141 dosage chart.

Do side effects change with dose, and does timing matter?

Yes. The phase 2b dose-ranging study found a clear dose-response relationship: higher doses of bremelanotide produced more nausea and more discontinuations, while lower doses were better tolerated but with less consistent efficacy ^[3]. That's the trade-off underlying the approved 1.75 mg dose that made it into Vyleesi. The approved label allows one dose at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than eight doses per month ^[9][10]. Those limits aren't arbitrary; they're tied directly to the side effect and blood pressure data from the trials. Using it more often than that isn't studied and isn't something we'd suggest testing on yourself. If you're mapping out timing and want a walkthrough of the injection process itself, pt-141 peptide how to use covers the practical steps, and a pt-141 dosage calculator can help you sanity-check spacing between doses.

Are there any long-term or serious risks beyond the common side effects?

The known longer-term signal is skin darkening (hyperpigmentation), particularly on the face and gums, seen with repeated dosing in the clinical program ^[2]. It's uncommon but documented, and it's the one effect that may persist rather than fade after stopping. Separately, lab research has looked at melanocortin receptor activation in other contexts entirely: a 2024 study found that bremelanotide induced cell death in glioblastoma cells in vitro by suppressing survivin expression ^[17]. That's cell-culture cancer research, completely unrelated to HSDD treatment or to any risk finding in people taking the approved drug. We mention it only because it turns up in searches and shouldn't be confused with a safety signal in patients; it's basic science exploring melanocortin receptor biology, not a warning about Vyleesi. There's also ongoing interest in the melanocortin system generally, including a 2023 review in Nature Reviews Endocrinology on targeting it for metabolic disease ^[6], and genetic research on melanocortin receptor polymorphisms and inflammatory disease risk ^[18]. None of that changes Vyleesi's approved safety profile; it's context for why this receptor family gets so much research attention beyond sexual desire.

How should I source PT-141 to avoid unknown side effect risks?

The side effect data cited throughout this article comes from trials of the specific FDA-approved formulation, Vyleesi, dosed exactly as labeled ^{[1][2][9][10]}. Compounded or research-grade PT-141 bought outside a prescription pathway wasn't tested under those same conditions, so the side effect rates above may not transfer cleanly to a different source or purity. Bremelanotide is not on the FDA's 503A bulk drug substances list for compounding ^[19], which is worth knowing if you're evaluating where a product is coming from. Working through a licensed prescriber and pharmacy, rather than an unregulated seller, is the only way to actually match the conditions the safety data was generated under. Bremelanotide Rx points readers toward that provider-reviewed route, with Vyleesi dispensed through a licensed pharmacy partner rather than sourced independently. If you're researching where products are sold, our coverage of pt-141 peptide for sale amazon and pt 141 peptide for men near me walks through what to watch for.

Frequently asked questions

What is the most common side effect of PT-141?

Nausea, by a wide margin. It showed up in about 40% of women taking bremelanotide in the phase 3 RECONNECT trials, versus roughly 1-3% on placebo ^[1]. It's usually worse with the first dose or two and tends to ease with continued use, based on the pooled safety analysis across the drug's development program ^[2].

Does PT-141 cause flushing, and how long does it last?

Yes. Flushing (skin warmth and redness, often in the face) affected about 20% of women on bremelanotide in the main trials ^[1]. It's tied to the drug's central mechanism and dosing window, so it's transient, typically resolving within hours of the dose rather than persisting.

Are PT-141 nasal spray side effects worse than the injection?

Early bremelanotide research included intranasal dosing, with nausea and flushing as the core effects plus some nasal irritation ^[8]. The FDA-approved product (Vyleesi) is a subcutaneous injection, not a nasal spray ^[9][10], so trial-grade side effect data doesn't directly apply to nasal formulations sold outside that approval.

Is PT-141 safe for people with high blood pressure?

It's not recommended for people with uncontrolled hypertension or known cardiovascular disease, because it causes a transient, dose-related rise in blood pressure after each dose ^[12]. This is a labeled screening consideration, and it's one reason a prescriber evaluates cardiovascular history before starting it.

Can PT-141 cause permanent skin darkening?

Focal hyperpigmentation, mainly on the face and gums, has been reported with repeated dosing in bremelanotide's clinical development program and may not fully reverse after stopping ^[2]. It's uncommon, but it's the one side effect in the trial data with a possibly lasting effect rather than a transient one.

Why does PT-141 cause nausea if it's meant to increase desire?

Because bremelanotide works centrally, activating melanocortin receptors (mainly MC4R) in the brain rather than acting on blood vessels like sildenafil does ^[4][5]. Those same brain pathways touch appetite and autonomic regulation, which is the likely reason nausea and flushing, not vascular effects, dominate its side effect profile.

How is PT-141 different from Viagra in terms of side effects?

Sildenafil (Viagra) works on blood vessels via PDE5 inhibition, so its risks center on blood pressure drops, especially with nitrates. Bremelanotide works centrally on melanocortin receptors, so its main effects are nausea, flushing, and a transient blood pressure rise rather than a drop ^[4][12]. They're mechanistically unrelated drugs.

Do side effects get better the longer you use PT-141?

For nausea specifically, yes, according to the pooled safety analysis across bremelanotide's clinical trials, tolerability improved with continued dosing after the first one or two uses ^[2]. Flushing and headache didn't show as clear a pattern of easing over time in the available trial reporting.

Are PT-141 side effects worse for men than women?

Nobody actually knows at the same evidence quality. Vyleesi's approval and its side effect rates come entirely from trials in premenopausal women with HSDD ^[1][9][10]. Use in men is off-label, and there's no phase 3-scale safety dataset for men, so side effect comparisons by sex aren't supported by controlled data.

What percentage of people stop taking PT-141 because of side effects?

Discontinuation due to nausea was notable in the phase 2b dose-ranging study, particularly at higher doses, where nausea rates and dropout both climbed ^[3]. Exact discontinuation percentages varied by dose tested; lower, approved-range doses were tolerated better than the highest doses studied.

Can PT-141 side effects be reduced by adjusting the dose or timing?

The approved label caps dosing at one injection at least 45 minutes before activity, no more than once per 24 hours, and no more than 8 times a month ^[9][10], limits set based on the trial dose-response data showing higher doses caused more nausea ^[3]. Staying within labeled limits is the main lever for managing side effects.

Is nausea from PT-141 dangerous or does it need treatment?

In the trials, nausea was mostly mild to moderate and self-limiting rather than requiring medical treatment ^[1][2]. It's the leading reason people stop the drug by choice, but it wasn't reported as a serious adverse event category in the trial data.

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): RECONNECT phase 3 trials reported nausea in roughly 40% and flushing in roughly 20% of women on bremelanotide versus low single digits on placebo
2. Journal of Women's Health, 2022 (PMID 35147466): Pooled safety analysis across the bremelanotide clinical development program shows nausea and flushing as dominant effects, easing with continued use, with hyperpigmentation flagged as a monitored, possibly persistent effect
3. The Journal of Sexual Medicine, 2019 (PMID 31277966): Phase 2b dose-ranging study found nausea and discontinuation rates rose with higher bremelanotide doses
4. CNS Spectrums, 2022 (PMID 33455598): Bremelanotide's neurobiology works through central melanocortin receptor activation rather than a vascular mechanism
5. Biomolecules, 2022 (PMID 36291616): Melanocortin receptor ligands, including MC4R agonists, act through central receptor pathways distinct from vascular drug targets
6. Nature Reviews Endocrinology, 2023 (PMID 37365323): The central melanocortin system, the same target as bremelanotide, is being explored for metabolic disorder treatment, explaining appetite-adjacent side effects
7. Diabetes, Obesity & Metabolism, 2022 (PMID 35170192): Phase 1 trials found bremelanotide had measurable effects on body weight in obese women, tied to melanocortin receptor activity
8. PubMed record, 2006 (PMID 31369224): Early bremelanotide development included intranasal dosing studies before the subcutaneous injection became the approved route
9. Drugs, 2019, Bremelanotide: First Approval (PMID 31429064): Bremelanotide was approved as Vyleesi, a subcutaneous injection, specifically for premenopausal women with HSDD
10. The Annals of Pharmacotherapy, 2020 (PMID 31893927): Vyleesi's approved label limits dosing to one injection at least 45 minutes before activity, max one per 24 hours, max 8 per month
11. Journal of Controlled Release, 2025 (PMID 40513668): A biodegradable buccal patch has been studied as an alternative peptide delivery method, illustrating how delivery route affects absorption and side effect timing
12. Medicina (Kaunas), 2022 (PMID 35630054): Bremelanotide causes a transient, dose-related rise in blood pressure and is not recommended for uncontrolled hypertension or cardiovascular disease
13. Drug and Therapeutics Bulletin, 2021 (PMID 34642243): Analysis argues that comparing bremelanotide to flibanserin as regulatory precedent overlooks real differences in efficacy and side effect character
14. The Medical Letter on Drugs and Therapeutics, 2019 (PMID 31381550): Clinical review of Vyleesi's approved use and side effect profile compared to other HSDD treatments
15. Journal of Sex Research, 2021 (PMID 33678061): Re-analysis of phase 3 bremelanotide trials raised concerns about the size of efficacy relative to side effect burden
16. Journal of Sex Research, 2024 (PMID 36809187): Published critique titled 'Small Effects, Questionable Outcomes' questions the clinical significance of bremelanotide's trial results
17. Anticancer Research, 2024 (PMID 39197897): Laboratory study found bremelanotide induced cell death in glioblastoma cells via survivin suppression, unrelated to HSDD treatment safety
18. Diseases (Basel), 2025 (PMID 41002740): Melanocortin receptor gene polymorphisms are associated with inflammatory traits and disease, providing broader context on the receptor family
19. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Bremelanotide is not included on the FDA's 503A bulk drug substances list for compounding